Evidence map›Paper›PMID 42038481›Full record

ArticleACS central science2026

Proximity-Induced Rewiring of Oncogenic Kinase Triggers Apoptosis.

Manuel L Merz, Veronika M Shoba, Rajaiah Pergu, Zachary C Severance, Dhanushka N P Munkanatta Godage, Arghya Deb, Hui Si Kwok, Prashant Singh, Sameek Singh, Jonathan B Allen and 17 more

Abstract read
In one paragraph

Article in ACS central science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Manuel L MerzChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.ORCID https://orcid.org/0000-0001-7986-890X
Veronika M ShobaChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Rajaiah PerguChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.ORCID https://orcid.org/0000-0002-7577-5914
Zachary C SeveranceChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Dhanushka N P Munkanatta GodageChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Arghya DebChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.ORCID https://orcid.org/0000-0001-7607-3941
Hui Si KwokDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.ORCID https://orcid.org/0000-0002-2858-8876
Prashant SinghChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.ORCID https://orcid.org/0009-0002-8893-2373
Sameek SinghChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Jonathan B AllenDepartment of Chemistry, Boston University, Boston, Massachusetts 02215, United States.
Wenzhi TianChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Pallavi M GosaviDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.
Santosh K ChaudharyChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Viktoriya AnokhinaChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Ellen L WeisbergDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.ORCID https://orcid.org/0000-0002-5679-9531
N Connor PayneDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.ORCID https://orcid.org/0000-0001-9513-6194
Yao HeBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Rohil DhaliwalChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Reilly OsadcheyDepartment of Chemistry, Boston University, Boston, Massachusetts 02215, United States.ORCID https://orcid.org/0000-0001-6011-1771
Mrinal ShekharCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.ORCID https://orcid.org/0000-0001-8089-8858
Ralph MazitschekBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Matthew G ReesBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Qiang CuiDepartment of Chemistry, Boston University, Boston, Massachusetts 02215, United States.ORCID https://orcid.org/0000-0001-6214-5211
James D GriffinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Brian B LiauDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.ORCID https://orcid.org/0000-0002-2985-462X
Amit ChoudharyChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.ORCID https://orcid.org/0000-0002-8437-0150

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
NCI NIH HHS P01 CA066996
6 · The paper itself

Abstract

The active site's electric field is integral to enzymatic catalysis (e.g., substrate recognition), and nature employs charge-altering post-translational modifications (e.g., phosphorylation) to perturb this electric field and regulate enzymes. A chromosomal translocation converts Abelson kinase (ABL) to BCR-ABL, the hyperactivity of which drives several cancers. Here, we developed a small molecule, BRD8833, that induces BCR-ABL phosphorylation, which perturbs its active site's electric field with loss of hyperactivity. Unlike "occupancy-driven" inhibitors that require stoichiometric concentrations, BRD8833 operates through an event-driven, substoichiometric mechanism by inducing the proximity between two BCR-ABL molecules to trigger the inhibitory phosphorylation and selective apoptosis of BCR-ABL-dependent cancer cells. Furthermore, BRD8833 is effective against other oncogenic ABL fusions or clinically observed resistance mutations, including those to occupancy-driven drugs with the same binding site as BRD8833, suggesting differences in their resistance mechanisms. These studies lay the foundation for electric-field and "event-driven" modalities to control hyperactive enzymes with orthogonal resistance mechanisms to occupancy-driven drugs.

Identifiers

PMID42038481
PMCPMC13107213

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.